CNAT—(-64%/AH)—fails in two more NASH phase-2b trials—that makes four phase-2b failures in all and no successes—discontinues Emricasan development—implements 40% layoff and “strategic restructuring”:
I owned a small position in CNAT a few years ago, but fortunately got out when the (misguided) phase-2b program was announced in late 2015 (#msg-118264572).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.